Bacterial Ghosts as antigen and drug delivery system for ocular surface diseases: Effective internalization of Bacterial Ghosts by human conjunctival epithelial cells

Journal of Biotechnology

Volumn 153, Issue 3-4, 2011, Pages 167-175

  Kudela, Pavol ^a,c,d   Koller, Verena Juliana ^a,c   Mayr, Ulrike Beate ^c   Nepp, Johannes ^a   Lubitz, Werner ^c,e   Barisani Asenbauer, Talin ^a,b,f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BIRD C GmbH and CoKG   (Austria)

^d CANCER RESEARCH INSTITUTE   (Slovakia)

^e UNIVERSITY OF VIENNA   (Austria)

^f Laura Bassi Centre of Expertise   (Austria)

Author keywords

Bacterial Ghosts; Conjunctiva; Delivery system; Ocular surface; Toxicity

Indexed keywords

BACTERIAL CELLS; BACTERIAL GHOSTS; BACTERIAL SPECIES; CARRIER SYSTEMS; CLASS I; CLASS II; CONJUNCTIVA; CYTOTOXIC; CYTOTOXIC EFFECTS; DELIVERY SYSTEM; DNA TRANSFER; DRUG DELIVERY SYSTEM; EPITHELIAL CELLS; GRAM-NEGATIVE BACTERIA; HIGH CAPACITY; HIGH RATE; IN-VITRO; OCULAR SURFACE; SURFACE APPLICATIONS; VACCINE DEVELOPMENT;

BACTERIOLOGY; CELL CULTURE; CELLS; CYTOTOXICITY; DRUG DELIVERY;

BACTERIA;

ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; BACTERIAL CELL; BACTERIAL MEMBRANE; BACTERIUM; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; EPITHELIUM CELL; EYE DISEASE; FEMALE; GRAM NEGATIVE BACTERIUM; HOST; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TEMPERATURE; INTERNALIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, TOPICAL; ANALYSIS OF VARIANCE; ANTIGENS; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; CONJUNCTIVA; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MANNHEIMIA HAEMOLYTICA; OPHTHALMIC SOLUTIONS; PHAGOCYTOSIS; PROBIOTICS; SPECTROMETRY, FLUORESCENCE;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 79955785442     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.03.022     Document Type: Article

References (48)

1. Abtin A., Kudela P., Mayr U.B., Koller V.J., Mildner M., Tschachler E., Lubitz W. Escherichia coli ghosts promote innate immune responses in human keratinocytes. Biochem. Biophys. Res. Commun. 2010, 400:78-82.
2. Bryceson Y.T., March M.E., Barber D.F., Ljunggren H.G., Long E.O. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 2005, 202:1001-1012.
3. Camelo S., Kezic J., Shanley A., Rigby P., McMenamin P.G. Antigen from the anterior chamber of the eye travels in a soluble form to secondary lymphoid organs via lymphatic and vascular routes. Invest. Ophthalmol. Vis. Sci. 2006, 47:1039-1046.
4. Chung S.H., Kweon M.N., Lee H.K., Choi S.I., Yang J.Y., Kim E.K. Toll-like receptor 4 initiates an innate immune response to lipopolysaccharide in human conjunctival epithelial cells. Exp. Eye Res. 2009, 88:49-56.
5. Decker T., Muller M., Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 2005, 5:675-687.
6. Diebold Y., Calonge M., Enriquez de Salamanca A., Callejo S., Corrales R.M., Saez V., Siemasko K.F., Stern M.E. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest. Ophthalmol. Vis. Sci. 2003, 44:4263-4274.
7. Ebensen T., Paukner S., Link C., Kudela P., de Domenico C., Lubitz W., Guzman C.A. Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol. 2004, 172:6858-6865.
8. Eko F.O., Barisani-Asenbauer T., Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum. Vaccin. 2008, 4:176-183.
9. Eko F.O., Lubitz W., McMillan L., Ramey K., Moore T.T., Ananaba G.A., Lyn D., Black C.M., Igietseme J.U. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 2003, 21:1694-1703.
10. Eko F.O., Mayr U.B., Attridge S.R., Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J. Biotechnol. 2000, 83:115-123.
11. Eko F.O., Schukovskaya T., Lotzmanova E.Y., Firstova V.V., Emalyanova N.V., Klueva S.N., Kravtzov A.L., Livanova L.F., Kutyrev V.V., Igietseme J.U., Lubitz W. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 2003, 21:3663-3674.
12. Ekong E.E., Okenu D.N., Mania-Pramanik J., He Q., Igietseme J.U., Ananaba G.A., Lyn D., Black C., Eko F.O. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol. Med. Microbiol. 2009, 55:280-291.
13. Fruh K., Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol. 1999, 11:76-81.
14. Gaglia J.L., Greenfield E.A., Mattoo A., Sharpe A.H., Freeman G.J., Kuchroo V.K. Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J. Immunol. 2000, 165:6091-6098.
15. Gillette T.E., Chandler J.W., Greiner J.V. Langerhans cells of the ocular surface. Ophthalmology 1982, 89:700-711.
16. Haidinger W., Szostak M.P., Jechlinger W., Lubitz W. Online monitoring of Escherichia coli ghost production. Appl. Environ. Microbiol. 2003, 69:468-474.
17. Henker J., Laass M.W., Blokhin B.M., Maydannik V.G., Bolbot Y.K., Elze M., Wolff C., Schreiner A., Schulze J. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr. Infect. Dis. J. 2008, 27:494-499.
18. Hensel A., Huter V., Katinger A., Raza P., Strnistschie C., Roesler U., Brand E., Lubitz W. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 2000, 18:2945-2955.
19. Hingorani M., Metz D., Lightman S.L. Characterisation of the normal conjunctival leukocyte population. Exp. Eye Res. 1997, 64:905-912.
20. Hook C.E., Matyszak M.K., Gaston J.S. Infection of epithelial and dendritic cells by Chlamydia trachomatis results in IL-18 and IL-12 production, leading to interferon-gamma production by human natural killer cells. FEMS Immunol. Med. Microbiol. 2005, 45:113-120.
21. Huter V., Hensel A., Brand E., Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol. 2000, 83:161-172.
22. Jechlinger W., Haller C., Resch S., Hofmann A., Szostak M.P., Lubitz W. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine 2005, 23:3609-3617.
23. Jenkinson S.R., Williams N.A., Morgan D.J. The role of intercellular adhesion molecule-1/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses. J. Immunol. 2005, 174:3401-3407.
24. Katinger A., Lubitz W., Szostak M.P., Stadler M., Klein R., Indra A., Huter V., Hensel A. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J. Biotechnol. 1999, 73:251-260.
25. Knop E., Knop N. Anatomy and immunology of the ocular surface. Chem. Immunol. Allergy 2007, 92:36-49.
26. Knop E., Knop N., Claus P. Local production of secretory IgA in the eye-associated lymphoid tissue (EALT) of the normal human ocular surface. Invest. Ophthalmol. Vis. Sci. 2008, 49:2322-2329.
27. Kojima K., Ueta M., Hamuro J., Hozono Y., Kawasaki S., Yokoi N., Kinoshita S. Human conjunctival epithelial cells express functional Toll-like receptor 5. Br. J. Ophthalmol. 2008, 92:411-416.
28. Kudela P., Koller V.J., Lubitz W. Bacterial ghosts (BGs)-advanced antigen and drug delivery system. Vaccine 2010, 28:5760-5767.
29. Kudela P., Paukner S., Mayr U.B., Cholujova D., Kohl G., Schwarczova Z., Bizik J., Sedlak J., Lubitz W. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett. 2008, 262:54-63.
30. Langemann T., Koller V.J., Muhammad A., Kudela P., Mayr U.B., Lubitz W. The bacterial ghost platform system: production and applications. Bioeng. Bugs 2010, 1:326-336.
31. Lefor A.T., Fabian D.F. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model. J. Surg. Res. 1998, 75:49-53.
32. Lubitz W., Witte A., Eko F.O., Kamal M., Jechlinger W., Brand E., Marchart J., Haidinger W., Huter V., Felnerova D., Stralis-Alves N., Lechleitner S., Melzer H., Szostak M.P., Resch S., Mader H., Kuen B., Mayr B., Mayrhofer P., Geretschlager R., Haslberger A., Hensel A. Extended recombinant bacterial ghost system. J. Biotechnol. 1999, 73:261-273.
33. Mader H.J., Szostak M.P., Hensel A., Lubitz W., Haslberger A.G. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 1997, 15:195-202.
34. Marchart J., Rehagen M., Dropmann G., Szostak M.P., Alldinger S., Lechleitner S., Schlapp T., Resch S., Lubitz W. Protective immunity against pasteurellosis in cattle, induced by Pasteurella haemolytica ghosts. Vaccine 2003, 21:1415-1422.
35. Mayr U.B., Haller C., Haidinger W., Atrasheuskaya A., Bukin E., Lubitz W., Ignatyev G. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect. Immun. 2005, 73:4810-4817.
36. McIntosh R.S., Cade J.E., Al-Abed M., Shanmuganathan V., Gupta R., Bhan A., Tighe P.J., Dua H.S. The spectrum of antimicrobial peptide expression at the ocular surface. Invest. Ophthalmol. Vis. Sci. 2005, 46:1379-1385.
37. Paukner S., Kudela P., Kohl G., Schlapp T., Friedrichs S., Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol. Ther. 2005, 11:215-223.
38. Paukner S., Stiedl T., Kudela P., Bizik J., Al Laham F., Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert. Opin. Drug Deliv. 2006, 3:11-22.
39. Perrin P., Morgeaux S. Inactivation of DNA by beta-propiolactone. Biologicals 1995, 23:207-211.
40. Saalbach A., Klein C., Sleeman J., Sack U., Kauer F., Gebhardt C., Averbeck M., Anderegg U., Simon J.C. Dermal fibroblasts induce maturation of dendritic cells. J. Immunol. 2007, 178:4966-4974.
41. Seo K.Y., Han S.J., Cha H.R., Seo S.U., Song J.H., Chung S.H., Kweon M.N. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J. Immunol. 2010, 185:3610-3619.
42. Szostak M.P., Hensel A., Eko F.O., Klein R., Auer T., Mader H., Haslberger A., Bunka S., Wanner G., Lubitz W. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol. 1996, 44:161-170.
43. Tabrizi C.A., Walcher P., Mayr U.B., Stiedl T., Binder M., McGrath J., Lubitz W. Bacterial ghosts-biological particles as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 2004, 15:530-537.
44. Ueta M. Innate immunity of the ocular surface and ocular surface inflammatory disorders. Cornea 2008, 27(Suppl. 1):S31-S40.
45. Ueta M., Hamuro J., Kiyono H., Kinoshita S. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem. Biophys. Res. Commun. 2005, 331:285-294.
46. Van Seventer G.A., Shimizu Y., Horgan K.J., Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 1990, 144:4579-4586.
47. Walcher P., Cui X., Arrow J.A., Scobie S., Molinia F.C., Cowan P.E., Lubitz W., Duckworth J.A. Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (Trichosurus vulpecula). Vaccine 2008, 26:6832-6838.
48. Witte A., Wanner G., Sulzner M., Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch. Microbiol. 1992, 157:381-388.